

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/129334 A1

(51) International Patent Classification:
A61K 51/04 (2006.01) *C07K 5/087* (2006.01)
(21) International Application Number:
PCT/CA2024/051689

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:
18 December 2024 (18.12.2024)

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

(25) Filing Language: English
(26) Publication Language: English

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(30) Priority Data:
63/611,244 18 December 2023 (18.12.2023) US
63/611,246 18 December 2023 (18.12.2023) US
63/617,292 03 January 2024 (03.01.2024) US

(71) Applicant: **FUSION PHARMACEUTICALS INC.**
[CA/CA]; 270 Longwood Road South, Hamilton, Ontario L8P 0A6 (CA).

(72) Inventors: **O'LEARY, James**; 273 Watertown Street, Newton, Massachusetts 02458 (US). **BOBILEV, Dmitri**; 760 Dedham Street, Newton, Massachusetts 02459 (US). **SCHINDLER, Joanne Elizabeth Sarah**; 41 Oldfield Drive, Sherborn, Massachusetts 01770 (US). **RHODEN, John**; 317 Main Street, Hingham, Massachusetts 02043 (US).

(74) Agent: **SMART & BIGGAR LP**; P.O. Box 2999, Station D., 1000-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: PSMA-TARGETED RADIOPHARMACEUTICALS FOR TREATMENT OF CANCER

(57) Abstract: A treatment for patients having cancer expressing Prostate Cancer Specific Membrane Antigen (PSMA) is disclosed. Said treatment involves the use of an 225Ac-radioconjugate, in particular 225Ac-PSMA-I&T. A dosage regimen that entails more frequent administration of the 225Ac-radioconjugate at lower dose level may be employed. This involves the use of a dosage of 50-75 kBq/kg of body weight on a dosing schedule of every 4-6 weeks. A flat dosing may also be employed where the dose does not depend on the body weight of the subject. Such dosing improve the benefit/risk profile with fewer adverse events and less discontinuations, dosing interruptions and reductions in dose. Of particular importance is a reduction in salivary gland toxicity and xerostomia.



WO 2025/129334 A1